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Hypoxoside is the major diglucoside isolated from the 
corms of the plant family Hypoxidaceae. It contains an 
unusual E-pent-1-en-4-yne 5-carbon bridging unit with two 
distal catechol groups to which the glucose moieties are 
attached. It is non-toxic for BL6 mouse melanoma cells in 
tissue culture on condition that the fetal calf serum in the 
medium is heat-inactivated for 1 hour at 56°C in' order to 
destroy endogenous beta-glucosidase activity. The latter 
catalyses hypoxoside conversion to its cytotoxic 
aglucone, rooperol , which, when tested as a pure 
chemical , caused 50% inhibition of BL6 melanoma cell 
growth at 1 0 ~g/ml. Light and electron microscopy 
revealed that the cytotoxic effect of rooperol manifested 
as vacuolisation of the cytoplasm and formation of pores 
in the plasma membrane. Indications of apoptosis were 
also found. 
Pharmacokinetic studies on mice dosed intragastrically 
with hypoxoside showed that it was deconjugated by 
bacterial beta-glucosidase to form rooperol in the colon. 
Surprisingly, no hypoxoside or 'rooperol was detectable in 
the serum. Only phase /I biotransformation products 
(sulphates and glucuronides) were present in the portal 
blood and bile. In contrast, however, in human serum after 
oral ingestion of hypoxoside, the metabolites can reach 
relatively high concentrations. 
Rooperol metabolites isolated from human urine were 
non-toxic for BL6 melanoma cells in culture up to a 
concentration of 200 lJg/ml. In the presence of beta-
glucuronidase, which released rooperol from the 
metabolites, 50% growth inhibition was achieved at a 75 
~g/ml metabolite concentration. The supernatant of a 
human melanoma homogenate could also cause 
deconjugation of the metabolites to form rooperol. 
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It can be concluded from these findings that rooperol 
has promising properties as an oral prodrug for cancer 
therapy in humans given its complete first-pass metabolism 
into non-toxic conjugates which may be activated in 
tumours with high deconjugase activity. Rodent cancer 
models are, however, not applicable since rooperol 
metabolites are completely sequestered in the bile. 
S Atr Med J 1995; 85: 853-860. 
Up until now, cancer chemotherapy has been a 
disappointing trade-off between efficacy and toxicity 
because of the lack of tumour cell selective toxicity. No 
chemical agent has yet been discovered that selectively 
eradicates cancer cells without harming normal .cells. One 
approach to the solving of this intractable problem would be 
the use of a non-toxic prodrug that is selectively activated to 
become cytotoxic in the immediate vicinity of cancer cells, 
Although we do not profess to have found such an ideal 
agent, we wish to report our find ings on the plant 
diglucoside, hypoxoside, which has some features that we 
believe point in the right direction, 
Hypoxoside is the trivial name for (E}-1 , 5-bis(4' -13-0-
glucopyranosyloxy-3 '-hydroxyphenyl) pent-4-en-1 -yne (CAS 
Reg. No. 83643-94-1 ), which is a norlignan diglucoside 
isolated from the. corms of Hypoxis plants of the family 
Hypoxidaceae.',2 It is a pale yellow water-soluble crystalline 
compound3 and is readily converted to the more lipophi lic 
aglucone, rooperol, by beta-glucosidase action,·,2,4 This 
conversion is shown schematically in Fig. 1. 
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Fig. 1. The inactive diglucoside, hypoxoside, is deconjugated by 
beta-glucosidase to form the cytotoxic and lipophilic aglucone, 
roopero/. 
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We have isolated hypoxoside from the corms of members 
of the family Hypoxidaceae, especially H. rooperi and H. 
acuminata.4 The plants are herbaceous perennials with 
tuberous rhizomes or corms (up to 10 cm in diameter or 
length and weighing 2 kg) and abundant adventitious roots 
that enable them to survive under high-stress conditions 
such as winter drought and fire. Traditional uses in folk 
medicine have been reported, inter alia for the treatment of 
cancers, testicular tumours, prostate hypertrophy and 
urinary disease.' Members of the Hypoxidaceae fami ly are 
found mainly in the southern hemisphere, especially in 
Africa. 
A high-performance liquid chromatography (HPLC) 
purified sample of hypoxoside (compound NSC 61783) was 
submitted to the National Cancer Institute (NCI), Bethesda, 
USA, for evaluation (M. R. Boyd - Research report: In vitro 
screening data review checklist, compound NSC: 613783, 
Experiment ID: 8909NS63, Date tested: 10.4.89) using the 
new investigational in vitro disease-orientated primary 
antitumour screen.· The compound was found to inhibit the 
growth of all 60 human cancer cell lines tested. The mean 
concentration giving a 50% inhibition of growth was 8,0 
flg/ml. One non-small-cell lung cancer cell line (NCI-H522) 
was about 14 times more sensitive than the average for all 
the cell lines tested and showed 50% inhibition of growth at 
0,6 flg/ml and complete inhibition at 1,8 flg/ml. Sub-panels 
of non-small-cell lung cancer and melanoma cells showed a 
statistically significant measure of differential sensitivity in 
respect of 50% growth inhibition compared with the other 
sub-panels tested. 
HPLC-purified hypoxoside was also evaluated by the 
Huntingdon Research Centre, England, by means of an in 
vitro clonogenic assay employing five tumour cell lines of 
human origin (P. F. Uphill and S. A. Crowther - Research 
report: A study of the cytotoxicity of two novel compounds 
against five human tumour cell lines using a clonogenic 
assay. Huntingdon Research Centre Ltd, Report INI 
26/851646, 1986). Concentrations giving 50% inhibition (IDJ 
of colony formation with cells derived from carcinomas of 
the colon , uterus and breast and with a melanoma cell line 
were in the range of 4,1 - 8,2 flg/ml , while a non-small-cell 
lung cancer cell line (ATCC HTB 53; A-427) proved most 
sensitive, giving an ID50 of 1,1 flg/ ml. 
Experiments at our laboratories confirmed that 
hypoxoside was cytotoxic for murine and human melanoma 
cells lines in vitro , but surprisingly it was found that this 
cytotoxicity was dependent on the deconjugation of the 
diglucoside by an endogenous, heat-labile, beta-glucosidase 
in fetal calf serum (FCS) to form the toxic aglucone, 
rooperol. ' When the FCS was pre-heated at 56°C for 1 hour 
or more this enzyme' activity was abolished and 100 flg/ ml of 
hypoxoside were without cytotoxic effect but could be 
activated by the addition of exogenous beta-glucosidase. 
Consequently, we surmise that in experiments conducted 
at the NCI and Huntingdon Research Laboratories, the 
reported cytotoxicity was caused by the conversion of 
hypoxoside to rooperol because the researchers were 
unaware of the endogenous beta-glucosidase in FCS. 
Therefore, evidence that hypoxoside itself was cytotoxic was 
erroneous in that the real cytotoxic moiety was the 
aglucone, rooperol. 
In this report we first present morphological data on the 
cytotoxic effect of rooperol on melanoma cells in culture and 
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then focus on the metabolism of orally ingested hypoxoside 
in mice, compared with humans. The data support a 
possible mechanism whereby hypoxoside could act as a 
latent prod rug for selective cancer therapy in humans. 
Materials and methods 
Materials 
The isolation of hypoxoside, preparation of rooperol and 
human urinary metabolites of rooperol were done as -
described earlier" Beta-glucuronidase was purchased from 
Seravac (South Africa). 
B16-F10-BL6 mouse melanoma cells· were a gift from 
Dr I. J. Fidler, Department of Cell Biology, MD AndersGn 
Hospital and Tumor Institute, Houston, Texas; the UeT-Mel 1 
human melanoma cells were a gift from Dr L. Wilso~ of the 
Department of Clinical Science, University of Cape Town" 
C57BU6J mice came originally from Jackson .:' 
Laboratories, Ann Arbor, Michigan and were subsequently 
inbred at the Research Institute for Nutritional Diseases of 
the MRC in Tygerberg. 
Morphological studies 
Mouse (BL6) and human (UCT-Mel 1) melanoma cells were 
cultured in 24 multi-well plates (Falcon) at 37"C in a 
humidified 5% CO2 atmosphere in air in an automatically 
controlled CO2 incubator (Forma). The culture medium 
containing 1 ml of McCoy's 5A medium (Flow Laboratories) 
was supplemented with 10% FCS (Gibco) which had been 
heated at 56°C for 30 minutes, 100 flg/ ml streptomycin, 
100 fl/ml penicillin and sodium bicarbonate (2,25 g/I). 
Twenty-four hours after plating, the cells were exposed to a 
final concentration of 50 flg/ml of hypoxoside and 
photographed every 2 hours for 24 hours with an inverted 
phase-contrast microscope attached to a camera (Nikon). 
For transmission electron microscopy, cells were cultured 
in 25 cm2 flasks (Falcon). After 24 hours' exposure to 
50 flg/ml hypoxoside they were released with trypsin-EDTA, 
centrifuged at 500 g for 1 b minutes and fixed in 2,5% 
glutaraldehyde in 0,05M sodium phosphate buffer, pH 7,2 
for 4 hours, postfixed in 1 % osmium tetroxide for 2 hours, 
washed in distilled water and stained in 5% aqueous uranyl 
acetate; this was followed by dehydration through a series 
of graded ethanol solutions, before cells were cleared in 
propylene oxide and embedded in an Epon/Araldite mixture. 
Ultrathin sections were picked up on uncoated copper grids, 
stained in lead citrate for 1 - 2 minutes and examined with 
an Hitachi H-300 electron microscope. 
For scanning electron microscopy, cells were grown on 
glass coverslips which had been rinsed in ethanol , dried and 
pre-incubated for 24 hours in 100% FCS. After 24 hours' 
exposure to 50 flg/ ml hypoxoside, the coverslips with 
attached cells were gently rinsed in phosphate-buffered 
saline and fixed for 2 hours at 4°C in 2,5% glutaraldehyde 
buffered at pH 7,2 in 0,1 M phosphate buffer. The coverslips 
were dehydrated through a graded series of ethanol 
solutions, critically dried and coated with gold-platinum 
according to standard practice. Cells were viewed with a 
Cambridge 180 Stereoscan microscope. 
• 
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Growth inhibition studies 
The effect of human urinary rooperol metabolites on the 
growth of BL6 melanoma cells was tested in 96 multiwell 
plates, plated at 5 x 103 cells in 200 ~I of McCoy's 5A 
medium (Flow Laboratories, Ayrshire, Scotland) with 10% of 
FCS which was heat-inactivated. Exogenous beta-
glucuronidase was added to a final concentration of 100 
~g/ml. After incubation for 72 hours, viable cells in each well 
were quantified by an adaption of the tetrazolium assay 
described by Oenizot and Lang'O as previously outlined.' 
Pharmacokinetic studies 
Hypoxoside (3 mg in 0,2 ml normal saline) was administered 
intragastrically to adult C57BU6J male mice 3 hours prior to 
necropsy. Samples were collected and prepared for HPLC 
analyses by mixing with guanidine hydrochloride 
pretreatment reagent (PT) according to the methodology 
developed by Kruger et a/. " Urine (20 ~I) was mixed with 
480 ~I PT; 70 ~I serum with 430 ~I PT; bile was removed 
from the gall bladder with a 26-gauge needle attached to a 1 
mi· tuberculin syringe containing 500 ~I PT; 1 g faeces was 
extracted with 12 ml methanol and 100 ~ I were mixed with 
400 ~I PT. Heparinised portal blood was collected from 9 
mice given 12 mg hypoxoside intragastrically 3 hours prior 
to necropsy; the plasma was Iyophilised, extracted with 5 ml 
methanol which was evaporated under a stream of nitrogen, 
the residue dissolved in 50 ~I methanol and mixed with 450 
111 PT reagent. 
Tumour sample 
A biopsy (100 mg) of an advanced human melanoma of the 
lower leg was homogenised in 1 ml of 0,1 M sodium acetate 
buffer pH 5,5 and centrifuged at 3 000 rpm for 10 minutes. 
Fifty micrograms human rooperol metabolite A, a 
diglucuronide of rooperol : were added to 0,5 ml of the 
supernatant and incubated for 20 hours at 37°C. One 
hundred microlitres of the incubation mixture were analysed 
by HPLC as described." 
Resutts 
Morphological studies 
With the use of phase contrast microscopy, destruction of 
BL6 and UCT-Mel 1 melanoma cells could be visualised over 
a period of 24 hours after 50 ~g/ml of hypoxoside were 
added to medium containing FCS that was heat-inactivated 
for only 30 minutes. The earliest signs of aberrant 
morphology in the BL6 cells occurred after about 12 hours · 
when it was noticed that the majority of cells assumed a 
flattened appearance with vacuoles forming 'empty spaces' 
in the cytoplasm of about 10% of the cells. At the same time 
the chromatin of round and shiny cells undergoing mitosis 
appeared amorphous, while in control cells without 
hypoxoside distinct metaphase chromosome plates could 
be discerned (Fig. 2A v. Fig. 2B; broad arrows). After about 
16 hours more than 50% of the cells showed vacuoles in the 
cytoplasm (Fig. 2C) and after 24 hours most of the cells 
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attached to the substrate contained large vacuoles and 
appeared to be disintegrating (Fig. 20; fine arrows). The 
rounded cells appeared intact with amorphous chromatin 
clumps in the centre (Fig. 20; broad arrows). 
Transmission electron microscopy of melanoma cells 24 
hours after exposure to 50 ~g/m l of hypoxoside showeO 
various features. Most irregular cells showed vacuoles in the 
cytoplasm (Fig. 3A; arrows) which either appeared to be 
empty or contained amorphous material (Fig. 3B). 
Mitochondria appeared to be empty or contained 
disintegrating cristae (Fig. 3C; arrows). Some cells had a 
condensed cytoplasm and fragmented nucleus (Fig. 3D) 
while others had an accentuated irregular outline (Fig. 3E) or 
a very smooth outline with condensed cytoplasm and 
chromatin with numerous vacuoles, of which two appeared 
to cause holes to form in the outer membrane (Fig. 3F). 
Scanning electron microscopy showed rounded control 
human UCT-Mel 1 melanoma cells attached to the glass 
substrate by thin microvill i, which also covered the surface 
of the cell (Fig . 4A). Similar cells exposed to hypoxoside, 
which was deconjugated to form rooperol by the 
endogenous beta-glucosidase, showed a smooth exterior 
apparently punctured by holes 0,5 - 2 ~m in diameter (Fig. 
4B foreground, long arrow), or with detaching cytoplasmic 
protrusions (Fig. 4B background, short arrows) . 
Pharmacokinetic studies 
HPLC analyses of mouse serum and urine 3 hours after 
epigastric dosing of 3 mg hypoxoside showed no 
hypoxoside, rooperol or any new peaks with the 
characteristic UV absorption spectrum of hypoxoside. Of 
particular interest, however, was the finding that methanol 
extracts of faeces showed that hypoxoside had been 
deconjugated to form rooperol (Fig. 5). Identification of the 
peaks in Fig. 5 was described by Kruger et a/.4 Bile showed 
three new fractions with hypoxoside-like UV absorbance 
spectra (Fig. 6) comparable to those found previously in 
human serum by Kruger et a/.4 The main peak (B) found in 
the bile was also present in portal blood of mice dosed 
epigastrically with 12 mg hypoxoside 3 hours prior to 
necropsy. No rooperol was detected in the portal blood. 
Studies with human metabolites of 
rooperol 
Human urinary metabolites of rooperol comparable to those 
found in the bile of mice shown in Fig. 6 were isolated with 
C,,-bonded silica' and incubated with BL6 mouse melanoma 
cells in the presence and absence of exogenous beta-
glucuronidase. Fig. 7 shows that in a concentration of up to 
200 ~g/ml the urinary metabolites had no inhibitory effect on 
cell proliferation, while in the presence of 1 00 ~g/ml of 
added beta-glucuronidase, 50% growth inhibition occurred 
at about 75 ~g/ml of the metabolites. HPLC analyses of the 
tissue culture fluid 72 hours after incubation showed that 
without beta-glucuronidase the metabolite pattern remained 
unchanged (Fig. 8; upper chromatogram) while in the 
presence of the enzyme a major shift occurred in terms of 
the disappearance of the main metabolite peaks and the 
appearance of new peaks with longer retention times (0, E, 
F, G and H in the lower chromatogram of Fig. 8). 
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Fig. 2. Phase contrast micrographs of BL-6 mouse melanoma cells exposed to 50 jJg/ml hypoxoside in medium with 10% non-heat-
inactivated FCS, conta ining endogenous beta-glucosidase causing increasing amounts of rooperol to be formed,' resulting in cell pathology. 
Normal cells in mitosis conta ined recogn isable metaphase plates (A - broad arrow). After 12 hours, treated cells in mitosis contained 
amorphous chromatin clumps (B - arrows). Flat cells showed extensive vacuolisation of the cy10plasm (C - arrows) after 16 hours, while 
after 24 hours most cells conta ined massive vacuoles (0 - fine arrows) and appeared to be disintegrating. Rounded cells had a smooth 
out line with condensed amorphous chromatin clumps (0 - broad arrows). 
Discussion 
Morphological studies 
Morphological studies of the effect of activated hypoxoside 
on melanoma cells in culture highlight the effect of rooperol, 
which is progressively released from hypoxoside as a result 
of deconjugation by endogenous beta-glucosidase.' 
Comparable terminal morphological effects were also seen 
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when rooperol was added directly to the cells, but we 
believe that the gradual and cumulative effects seen here 
are more relevant because they pertain to a situation where 
an inactive drug (hypoxoside) is enzymatically converted into 
an active drug (rooperol) in the immediate vicinity of cancer 
cells. This is the situation one would hope to achieve in vivo 
in humans during activation of the metabolites of rooperol. 
The morphological effects seem to fall into two categories, 





Fig. 3. Transmission electron micrographs of BL6 mouse and UCT-Mel 1 human melanoma cells 24 hours after exposure to 50 Ilglml of 
hypoxoside in medium containing endogenous beta-glucosidase. Various features are presented; vacuoles in the cy10plasm of a BL6 cell (A 
- arrows); amorphous material in a vacuole of a BL6 cell (B); disintegrating mitochondria in a BL6 cell (C - arrows); a BL6 cell with 
condensed cy10plasm and fragmented nucleus (D); an UCT-Mel 1 cell with an irregular outline (E) and a rounded UCT-Mel 1 cell with a 
smooth outline, condensed cy10plasm and nucleus and two peripheral vacuoles (arrows) which appear to be forming pores in the plasma 
membrane (F). Figs 3D, E and F suggest that rooperol induced apoptosis. 
SAMJ Volume 85 No.9 September 1995 
- ~ 
Fig. 4. Scanning electron micrographs of a normal, rounded UCT-Mel 1 melanoma cell attached to a glass coverslip (A) and a similar cell 24 
hours after exposure to 50 J.Ig/ml of hypoxoside in medium containing endogenous beta-glucosidase (B). Distinct pores are present in the 
smooth plasma membrane of the cell in the foreground (long arrow) while the adjacent cell appears to be shedding membrane enclos~_ll spheres 
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Fig. 5. HPLC chromatogram of a methanol extract of mouse faeces 
showing a residual trace of hypoxoside (1), hypoxoside 
monoglucoside (2) , rooperol (3), dehydroxyrooperol (4) and bis-
dehydroxy-rooperol (5). 
not. In both melanoma cell lines studied (BL6 and UCT-Mel 
1), cells undergoing mitosis are spherically shaped with 
clearly visible sets of chromosomes arranged in the 
metaphase plate (Fig. 2A; broad arrow). Such cells seemed 
to undergo the first detectable changes in the presence of 
activated hypoxoside. After 12 hours, chromosome sets 
could no longer be seen clearly and the rounded cells 
contained an amorphous mass of chromatin (Fig. 2B). This 
suggests that rooperol may disturb the mechanisms 
involved in the maintenance of chromosome structural 
integrity and segregation during mitosis. Scanning electron 
microscopy showed rounded UCT-Mel 1 melanoma cells, 
presumed to have entered mitosis, with distinct holes in the 
smooth outer membrane (Fig. 4B). This suggests that over 
and above any effect on the organisation of the chromatin, 
rooperol also destabilises the outer membrane to the extent 
that it is severely punctured. 
It is important to note that f lattened cells, presumably not 
in mitosis, were also deleteriously affected by rooperol in 
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terms of the extensive, cumulative formation of vacuoles in 
the cytoplasm and ' blebs appearing on the outer membrane. 
It is possible that the detachment of these blebs may have 
caused the holes in the outer membrane (Fig. 3E; arrows). 
Some cells also showed condensation of the cytoplasm and 
chromatin (Figs 3B and 3F) reminiscent of cells undergoing 
apoptosis.'2 
Mode of action of roopero/ 
The molecular basis of rooperol cytotoxicity still needs to be 
clarified. Previous biochemical studies have shown that 
rooperol is a potent inhibitor of leukotriene synthesis in 
polymorphonuclear leucocytes at concentrations of 1 !-1M or 
less.'3 However, the synthesis of cyclo-oxygenase products, 
TxB2 and PG02, were inhibited only at concentrations 
between 10 and 100 !-Im. '3 Rooperol-induced growth 
inhibition occurred at concentrations ranging from about 
0,6 to 8 !-Ig/ml, which is equivalent to about 1 - 13 !-1M. It is 
thererore possible that the morphological effects described 
here were triggered by an inhibition of leukotriene synthesis. 
Other workers have also reported inhibition of cancer cell 
proliferation by inhibitors of leukotriene synthesis which are 
not chemically related to rooperol.14 Nordihydroguiaretic acid 
(NOGA), however, has a chemical structure related to rooperol 
and also inhibits leukotriene synthesis. '3 Miller et al.'5 showed 
that NOGA inhibited the growth of HL-60, K-562 and KG-1 
human leukaemia cell lines at concentrations ranging from 
5 to 10 !-1M. 
Another possibility is that rooperol may have been 
oxidised to form reactive semiquinone radicals that could 
have damaged membranes directly. It was shown earlier'3 
that rooperol could form a semiquinone under in vitro 
oxidative conditions which caused lysis of red blood cells. 
Results reported by the NCI suggested that rooperol 
released from deconjugated hypoxoside in tissue culture 
affected the NCI-H522 non-small-cell lung cancer cell line at 
about a 14-fold lower concentration than most of the other 
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Fig. 6. HPLC chromatogram of mouse bile 3 hours after epigastric 
dosing of 3 mg hypoxoside. The three peaks (A, 8 , C) represent 
conjugated metabolites of rooperol characterised as di-
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Fig. 7. Proliferation of 8L6 mouse melanoma cells in the presence 
of human urinary rooperol metabolites (x--x) and after addition 
of 100 !lg/ml beta-glucuronidase (0-0). The decrease in 
absorbance at 570 nm was m·easured using the MTT technique 
described in the Methods section and represents inhibition of 
grow1h. About 75 !lg/ml of metabolites caused 50% grow1h 
inhibition after 72 hours of incubation. 
rooperol may be determined to a large extent by the 
molecular characteristics of the target cells involved and that 
it is not a general cytotoxin such as cyanide. Comparative 
molecular studies of sensitive and very sensitive cell lines 
are presently being undertaken by us in order to elucidate 
the exact mode of action of rooperol as a cytotoxic drug. 
Pharmacokinetics of hypoxoside in 
mice 
Hypoxoside was not absorbed as such into the bloodstream 
of mice because it was not detected in serum from the 
general circulation or from portal blood. However, clear-cut 
evidence was found that hypoxoside was deconjugated to 
form rooperol in the caecum and colon of the mouse. There 
is little doubt that this was due to beta-glucosidase enzymes 
of bacterial origin because after oral treatment of mice with 
clindamycin, no rooperol, only hypoxoside was found in the 
faeces (results not shown). 
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Fig. 8. HPLC chromatogram of human urinary rooperol metabolites 
72 hours after incubation without exogenous beta-glucuronidase 
(upper chromatogram) and with 100 !lg/ml exogenous beta-
glucuronidase (lower chromatogram). Major changes are the 
disappearance of peaks A and 8 and a 50% decrease in peak C and 
the increase of peaks at retention times (RTs) 11 ,0 min (0) and 12,1 
min (E) which have been shown to be monosulphates of rooperol.' 
Rooperol (RT = 12,6 min, peak F) is a minor peak while 
dehydroxyrooperol (RT = 14,1 min, peak G) and bis-
dehydroxyrooperol (RT = 15,4 min, peak H) are present as 
described.' 
The detection of new peaks in the bile of a mouse with UV 
absorbance spectra similar to hypoxoside and rooperol 
indicates that rooperol is absorbed and converted to new 
conjugates by phase II metabolism as reported by Kruger et 
al. for human serum.' The presence of the main metabolite 
peak in mouse portal blood suggests that roope.rol was also 
conjugated in the epithelial cells lining the caecum and 
colon. This interpretation is also supported by the absence 
of rooperol in blood from the general circulation or from the 
portal vein of the mouse. 
The general conclusion we draw from these data is that in 
mice, neither hypoxoside, rooperol nor rooperol metabolites 
enter the general circulation, and that consequently a rodent 
cancer model would be quite useless in determining any 
anti-cancer potential of hypoxoside. Indeed, numerous 
attempts to arrest the growth of various tumours in mice 
using oral doses of hypoxoside were unsuccessful (data not 
shown). 
The situation in humans is, however, strikingly different. 
Kruger et al.' showed that the metabolites which sequester 
in the bile of the mouse, appear in the serum of humans in 
relatively high concentrations. 
We conclude from these observations that biochemical 
mechanisms present in hepatocytes determine to what 
extent phase II conjugates of xenobiotics are excreted via 
the biliary or c irculatory systems and that in primates these 
mechanisr:ns allow a certain percentage of rooperol 
metabolites to enter the systemic bloodstream for excretion 
via the kidneys. In this respect, humans and rodents are 
quite d istinct. 
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Cytotoxicity of human roopero/ 
metabolites 
As was to be expected, high concentrations (200 ~g/ml) of 
rooperol metabolites (isolated from human urine) had no 
effect on the proliferation of melanoma cells in culture 
(Fig. 7), presumably because the cytotoxic potential of 
rooperol is latent as a result of the conjugated nature of the 
metabolites imparting a strong molecular charge which 
would impair the drug's entry into cells. 
Of crucial interest was whether the latent cytotoxicity of 
the rooperol metabolites could be unlocked in vivo, 
especially in the vicinity of cancer cells or in tumours. 
To test this possibility, beta-glucuronidase was added to 
8L6 melanoma cells in culture in the presence of rooperol 
metabolites. As shown in Fig. 7, at 1 00 ~g/ml of the 
metabolites, growth of the melanoma cells was inhibited by 
90%. In separate studies, not reported here, that used a 
clonogenic assay of 8L6 melanoma cells exposed to 
rooperol metabolites and the deconjugating enzymes, beta-
glucuronidase and aryl sulphatase, a 100% inhibition of 
colony formation was found and scanning electron 
microscopy revealed cells with holes in the membranes 
similar to those shown in Fig. 58. HPLC analysis of the 
products of beta-glucuronidase incubation with rooperol 
metabolites (Fig. 8) showed peaks with retention times 
longer than that of the metabolites, viz. 11 ,0 (D) and 12,1 
minutes (E). In a separate study: we showed that these 
peaks represent monosulphates of rooperol and 
dehydroxyrooperol after removal of glucuronic acid. The 
presence of peaks at retention times of 14,0 (G) and 15,4 
minutes (H) indicate that rooperol was formed, because 
these peaks are typical of dehydroxy- and bis-
dehydroxyrooperol , since they appear when hypoxoside or 
rooperol metabolites are deconjugated! The absence of 
rooperol per se (Fig. 8, lower chromatogram, F) is due to 
the duration of incubation of the cells (72 hours), because 
short-term incubation of rooperol metabolites with beta-
glucuronidase reveals rooperol in HPLC profiles (data not 
showri). It is thought that the absence of rooperol is due to 
its binding to cellular molecules and/or polymerisation, as 
suggested before. " 
After demonstrating that rooperol metabolites could be 
activated to destroy melanoma cells in the presence of beta-
glucuronidase it was of interest to know whether human 
tumours contained enzymes that could deconjugate the 
metabolites. Incubation of rooperol metabolites with an 
aqueous supernatant of a human melanoma resulted in the 
formation of the same peaks shown in Fig. 8 (lower 
chromatogram). 
Latent cytotoxicity of glucuronides derived from 
xenosidics in cancer therapy have been described by 
Connors and Whisson '6 who reported the cure of mice with 
advanced plasma cell tumours that were treated with aniline 
mustard, and the relationship between glucuronidase activity 
and tumour sensit ivity. They postulated that aniline mustard 
glucuronide, formed in the liver of the treated mice, could be 
cleaved to form the highly toxic hydroxy derivative by high 
levels of beta-glucuronidase in the tumours and that this 
sequence of events would produce a I·ocal activation of a 
potent cytotoxic drug within the tumour itself and the 
observed therapeutic effect. Subsequent to this, Young et 
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al.17 conducted a therapeutic trial of aniline mustard in 
patients with advanced cancer and compared the 
therapeutic resp.onse with cytochemical assessment of 
tumour cell beta-glucuronidase activity; they found a partial 
correlation. 
In conclusion, we believe that our studies have 
established a good motivation for the clinical evaluation of 
hypoxoside as an oral prodrug for cancer therapy in humans 
for three important reasons: (I) the detection of high 
concentrations of rooperol metabolites in human serum 
which were found to be non-toxic at high concentrations in 
tissue culture; (iI) demonstration that these metabolites ~_ 
could be activated to become cytotoxic for melanoma· cells 
in culture in the presence of beta-glucuronidase and that 
extracts from a human tumour could also deconjugate the 
metabolites; and (iii) the observation that mice were quite 
unsuitable as test animals for evaluating the in vivo ~otential 
of hypoxoside as a prod rug for cancer therapy, giv!:l-n the 
lack of rooperol metabolites in their blood. 
• This study was initiated and sponsored by Essential ,Sterolin 
Products according to an agreement entered into with the 
University of Stellenbosch. 
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